Leonardo Barbosa de Almeida1, Patrícia Fernandes Trevizan2, Mateus Camaroti Laterza2,3, Abrahão Elias Hallack Neto4,5, Ana Carolina Amaral de São José Perrone4,5, Daniel Godoy Martinez2,3. 1. Federal University of Juiz de Fora, Cardiovascular Research Unit and Exercise Physiology, José Lourenço Kelmer, s/n, Martelos, Juiz de Fora, 36036-900, Brazil. almeidalb@hotmail.com. 2. Federal University of Juiz de Fora, Cardiovascular Research Unit and Exercise Physiology, José Lourenço Kelmer, s/n, Martelos, Juiz de Fora, 36036-900, Brazil. 3. Master's Program on Rehabilitation Sciences, Federal University of Juiz de Fora, Juiz de Fora, Brazil. 4. Department of Hematology, Hemotherapy and Bone Marrow Transplantation, Federal University of Juiz de Fora, Juiz de Fora, Brazil. 5. Department of Clinical Medical, Federal University of Juiz de Fora, Juiz de Fora, Brazil.
Abstract
PURPOSE:Patients undergoing hematopoietic stem cell transplantation (HSCT) usually experienced respiratory muscle weakness. Inspiratory muscle training (IMT) at HSCT has not been studied yet. Thus, it is important to evaluate the safety, feasibility, and preliminary effectiveness of IMT for hospitalized patients undergoing HSCT with an unstable and acute clinical condition. METHODS: This is a randomized controlled feasibility study. Thirty-one hospitalized patients undergoing HSCT were randomized to the conventional physical rehabilitation (CON) or to the IMT group (conventional physical rehabilitation + IMT). IMT was carried out at 40% of maximal inspiratory pressure (MIP), 5 sessions weekly, 10-20 min/session. Primary outcomes were safety and feasibility (recruitment, adherence, and attrition rates) of IMT. Secondary outcomes were respiratory strength, respiratory rate, oxygen saturation, and frequency of patients with oxygen desaturation, bleeding, dyspnea, and acute pulmonary edema. RESULTS: Patients were allocated to the IMT (N = 15; 43.6 years) or to the CON group (N = 16; 46.6 years). The recruitment rate was 100%, the adherence rate was 91%, and attrition was 13% to IMT. Two events were observed in 126 IMT sessions (1.5%). MIP increased in the IMT group (P < 0.01). No differences were observed in respiratory rate and oxygen saturation between groups. Trends to negative outcomes were observed in the CON in comparison to IMT group for a need of oxygen therapy (18% vs. 6%), bleeding (12% vs. 6%), dyspnea (25% vs. 13%), and acute pulmonary edema (6% vs. 0%). CONCLUSIONS: IMT is safe, feasible, and improves the inspiratory muscle strength in hospitalized patients undergoing HSCT. TRIAL REGISTRATION: Clinical trial registration: NCT03373526.
RCT Entities:
PURPOSE:Patients undergoing hematopoietic stem cell transplantation (HSCT) usually experienced respiratory muscle weakness. Inspiratory muscle training (IMT) at HSCT has not been studied yet. Thus, it is important to evaluate the safety, feasibility, and preliminary effectiveness of IMT for hospitalized patients undergoing HSCT with an unstable and acute clinical condition. METHODS: This is a randomized controlled feasibility study. Thirty-one hospitalized patients undergoing HSCT were randomized to the conventional physical rehabilitation (CON) or to the IMT group (conventional physical rehabilitation + IMT). IMT was carried out at 40% of maximal inspiratory pressure (MIP), 5 sessions weekly, 10-20 min/session. Primary outcomes were safety and feasibility (recruitment, adherence, and attrition rates) of IMT. Secondary outcomes were respiratory strength, respiratory rate, oxygen saturation, and frequency of patients with oxygen desaturation, bleeding, dyspnea, and acute pulmonary edema. RESULTS:Patients were allocated to the IMT (N = 15; 43.6 years) or to the CON group (N = 16; 46.6 years). The recruitment rate was 100%, the adherence rate was 91%, and attrition was 13% to IMT. Two events were observed in 126 IMT sessions (1.5%). MIP increased in the IMT group (P < 0.01). No differences were observed in respiratory rate and oxygen saturation between groups. Trends to negative outcomes were observed in the CON in comparison to IMT group for a need of oxygen therapy (18% vs. 6%), bleeding (12% vs. 6%), dyspnea (25% vs. 13%), and acute pulmonary edema (6% vs. 0%). CONCLUSIONS: IMT is safe, feasible, and improves the inspiratory muscle strength in hospitalized patients undergoing HSCT. TRIAL REGISTRATION: Clinical trial registration: NCT03373526.
Authors: Erica Morales-Rodriguez; Txomin Pérez-Bilbao; Alejandro F San Juan; Jorge Lorenzo Calvo Journal: Int J Environ Res Public Health Date: 2022-01-24 Impact factor: 3.390
Authors: Prina Vira; Stephen R Samuel; Santosh Rai Pv; Pu Prakash Saxena; Sampath Kumar Amaravadi; Nagaraja Ravishankar; Diwakar D Balachandran Journal: Asian Pac J Cancer Prev Date: 2021-12-01